Drug Landscape ›
Coenzyme Q 10 ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 326
Most-reported reactions
Fatigue — 41 reports (12.58%) Diarrhoea — 38 reports (11.66%) Nausea — 36 reports (11.04%) Headache — 35 reports (10.74%) Asthenia — 33 reports (10.12%) Dizziness — 31 reports (9.51%) Eye Pain — 30 reports (9.2%) Dyspnoea — 28 reports (8.59%) Urinary Tract Infection — 28 reports (8.59%) Product Dose Omission Issue — 26 reports (7.98%)
Source database →
Coenzyme Q 10 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Coenzyme Q 10 approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Coenzyme Q 10 in United States?
Universitas Diponegoro is the originator. The local marketing authorisation holder may differ — check the official source linked above.